TW:NASDAQTradeweb Markets Inc. Analysis
Data as of 2026-08-01 - not real-time
$100.50
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Tradeweb Markets is trading near $100.5, just above its 20‑day ($100.34) and 50‑day ($100.16) simple moving averages, and the MACD histogram remains positive, signaling short‑term bullish momentum. RSI sits at 49.7, indicating the stock is neither overbought nor oversold, while volume is on an increasing trend, supporting the price action. However, the 30‑day volatility of 49.5% is unusually high for a financial‑services firm, and the computed beta of -0.20 suggests low correlation with broader market moves, adding a layer of idiosyncratic risk. On the valuation side, the market price exceeds the DCF‑derived fair value of $80.75 and trades at a forward P/E of 21.8 versus an industry average of 18, implying the stock is currently overvalued. Fundamental metrics are solid: revenue grew 9% YoY to $2.2 B, gross margin is an exceptional 93%, operating margin 44%, and the payout ratio is a modest 12% with a dividend yield of 0.56%, indicating dividend sustainability. Recent news highlights a suite of AI‑driven tools (Kalshi event‑contract pricing, TARA AI assistant) and a multi‑year partnership with professional golfer James Nicholas, underscoring Tradeweb’s push to deepen its data‑analytics moat and broaden brand visibility.
The Q2 2026 results showed sales up 9% YoY to $558.9 M and a non‑GAAP EPS of $0.97, beating consensus, while Goldman Sachs upgraded the stock to Buy with a new $146 price target, reinforcing analyst confidence. With a strong balance sheet (over $2 B cash, low debt) and a high ROE of 14%, the company is well‑positioned to capture further market share in electronic fixed‑income trading. Nonetheless, the high volatility and a price that already incorporates significant upside (27% upside vs DCF) suggest caution for short‑term traders, while the growth trajectory and durable cash flow support a longer‑term buy case.
The Q2 2026 results showed sales up 9% YoY to $558.9 M and a non‑GAAP EPS of $0.97, beating consensus, while Goldman Sachs upgraded the stock to Buy with a new $146 price target, reinforcing analyst confidence. With a strong balance sheet (over $2 B cash, low debt) and a high ROE of 14%, the company is well‑positioned to capture further market share in electronic fixed‑income trading. Nonetheless, the high volatility and a price that already incorporates significant upside (27% upside vs DCF) suggest caution for short‑term traders, while the growth trajectory and durable cash flow support a longer‑term buy case.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price marginally above short‑term moving averages
- High 30‑day volatility
- Bullish MACD but neutral RSI
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 9% revenue growth with ultra‑high margins
- Recent product launches expanding AI and event‑driven data
- Analyst upgrades and raised price targets
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Strong cash position and low leverage
- Sustainable dividend and low payout ratio
- Strategic positioning in electronic fixed‑income markets
Key Metrics & Analysis
Financial Health
Revenue Growth9.00%
Profit Margin40.70%
P/E Ratio24.0
ROE14.47%
ROA12.48%
Debt/Equity2.05
P/B Ratio3.2
Op. Cash Flow$1.2B
Industry P/E18.0
Technical Analysis
TrendNeutral
RSI49.7
Support$94.29
Resistance$108.75
MA 20$100.34
MA 50$100.16
MA 200$109.12
MACDBullish
VolumeIncreasing
Fear & Greed Index92.88
Valuation
Fair Value$80.75
Target Price$127.71
Upside/Downside27.08%
GradeOvervalued
TypeBlend
Dividend Yield0.56%
Risk Assessment
Beta-0.20
Volatility49.48%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.